Journal Articles
New England CEPAC

PDF cover

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

ICER collaborators and staff had findings on the cost-effectiveness of PCSK9 inhibitors for treatment of high cholesterol published in JAMA. Download the publication here (subscription required for full text).

View All Materials on this Topic or Go Back to View More Materials